

# Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

<https://marketpublishers.com/r/A23BD1EA44AEN.html>

Date: December 2016

Pages: 288

Price: US\$ 880.00 (Single User License)

ID: A23BD1EA44AEN

## Abstracts

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates (ADCs) in a tabular format by target, payload, R&D phase and company as of December 2016.

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Since our last ADC Competitor Analysis in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at the end of the year 2016. Among them are eight ADCs in late stage development or under regulatory review. More than 20 ADCs are in the IND stage or undergoing IND-enabling studies. This analysis identified further 58 preclinical stage ADC projects and 22 ADC discovery programs. However, the number of ADCs discontinued from clinical development also has increased.

The report furthermore lists the ADCs by target, drug payload, and by company portfolio.

Among the popular targets of ADC developments identified in the search are:

Her2

CD30

CD33

CD22

CD19

PSMA

5T4

EGF-R

CEACAM5

CD37

CD38

CD25

CD70

Mesothelin

c-Met

MUC16

CD123

Tissue Factor

TROP-2

FGF-R

## Ephrin-A

in addition to unique targets identified by companies with proprietary target discovery programs.

With the increasing number of ADCs in development and of companies with in-house ADC technology development, new payloads are being evaluated in early clinical studies.

The report includes a compilation of currently active as well as discontinued ADC R&D. In addition, the report lists company-specific R&D pipelines of ADCs. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,

Class of Compound (antibody, linker, payload),

Company,

Product Category,

Indication,

R&D Stage and

additional comments about latest results with a hyperlink leading to the source of information.

### **About Competitor Analysis Series:**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## Contents

### 1. ANTIBODY-DRUG CONJUGATES (ADCS) BY TARGET

Kadcyla Indication Pipeline

Her2

Adcetris Indication Pipeline

CD30

CD33

CD22

CD19

PSMA

5T4

EGF-R

CEACAM5

CD37

CD38

CD25

CD70

Mesothelin

c-Met

MUC16

CD123

Tissue Factor

TROP-2

FGF-R

Ephrin-A

Unique Targets of ADCs from Big Pharma & Biotech

Unique Targets of ADCs from Mid Size Biotech & Pharma

Unique Targets of ADCs from Small Biotech

Not Disclosed Targets of ADCs from Big Pharma & Biotech

Not Disclosed Targets of ADCs from Small Biotech

### 2. NON-ONCOLOGY INDICATIONS FOR ADCS

### 3. DISCONTINUED CLINICAL STAGE ANTIBODY-DRUG CONJUGATES

### 4. ADCS BY HIGHEST R&D PHASE

Approved and Late Stage Clinical Development  
Early Stage Clinical Development  
IND and Pre-IND Stage Development  
Preclinical Stage Development  
Discovery Stage

## **5. ADCS BY DRUG PAYLOAD**

Monomethyl Auristatin E and F (MMAE / MMAF)  
Other Auristatins  
Pyrrolobenzodiazepine (PBD)  
Other DNA Targeted Agents  
Maytansinoids  
Topoisomerase Inhibitors  
Other Microtubule/Mitosis Targeted Agents  
Other Cytotoxic Agents  
Other Types of Payloads  
Payload Not Disclosed or Specified

## **6. CORPORATE ANTIBODY-DRUG CONJUGATE R&D PIPELINES**

## I would like to order

Product name: Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

Product link: <https://marketpublishers.com/r/A23BD1EA44AEN.html>

Price: US\$ 880.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A23BD1EA44AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970